SARTORIUS AG : Q2 2018 preview: No surprises expected in Q2 18e, but downgrade to Reduce due to rich valuation
>Q2 2018e: we estimate the top line to grow 9.2%, EBITDA by 10% yoy - For Q2 2018e, we estimate Sartorius’s revenue at c.€ 394m, corresponding to a growth rate of 9.2% yoy (12.2% in cc; FX headwind: 3%), and underlying EBITDA growth of 10% yoy to € 100m (Q2 2017: € 90m). This translates into an underlying EBITDA margin of 25.4% (Q2 2017: 24.8%). We believe management will confirm its existing sales and earnings guidance for 2018, i.e. group sales growth of 9-12% ...Sartorius is a holding company, which is engaged as an international laboratory and process technology provider for the biotech, pharmaceutical and food industries. Co. has three segments: the Bioprocess Solutions, which provides solutions for the core process steps in biopharmaceutical production, focusing on the areas of activity of filtration, fluid management, fermentation, and purification; the Lab Products & Services, which serves both research and quality assurance laboratories across several different industries; and the Industrial Weighing, which concentrates on weighing and control applications in the manufacturing processes of the food, chemical and pharmaceutical sectors.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.